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ABSTRACT
MONTERO, D., and A. J. FLAMMER. Effect of Beta-blocker Treatment on V˙O2peak in Patients with Heart Failure. Med. Sci. Sports
Exerc., Vol. 50, No. 5, pp. 889–896, 2018. Purpose: In addition to prolonged life and reduced hospitalization rates, it is currently unclear
whether beta-blocker (BB) treatment modulates peak oxygen consumption (V˙O2peak), a hallmark of exercise capacity, in patients with
heart failure (HF). The main aim of this study is to determine the effect of BB treatment on V˙O2peak in HF patients. Methods: We
conducted a systematic search of MEDLINE, Scopus, and Web of Science since their inceptions until March 2017 for randomized
controlled trials (RCT) assessing the effect of BB treatment on V˙O2peak in chronic HF patients. A meta-analysis was performed to
ascertain the standardized mean difference (SMD) between the effects of BB and placebo treatment on V˙O2peak. Secondary outcomes
included peak exercise performance and New York Health Association functional class. Subgroup and meta-regression analyses assessed
potential moderating factors. Results: Fourteen RCT met the inclusion criteria (overall n = 616). Interventions comprised BB (n = 324) or
placebo (n = 292) administration lasting 3 to 24 months. Concomitant reported medication did not differ between HF patients assigned to
BB and placebo groups. After data pooling, V˙O2peak was preserved with BB compared with placebo treatment (SMD, j0.04; 95%
confidence interval (CI), j0.20 to 0.12; P = 0.61); heterogeneity among studies was not detected (I2 = 0%, P = 0.88). Peak exercise
performance was not altered (SMD, 0.02; 95% CI,j0.16 to 0.20; P = 0.85), whereas New York Health Association functional class was
reduced with BB compared with placebo (SMD,j0.54; 95% CI,j0.90 toj0.18; P = 0.003).Conclusions: According to evidence from
RCT, prolonged BB (B1-selective or nonselective) treatment does not affect V˙O2peak but improves functional status in HF patients. Key
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A
memorable challenge to the paradigm for the treat-
ment of heart failure (HF) materialized in the 1970s
(1,2). Beta-blockers (BB) were first administered in
HF patients by Swedish scientists relying on consistent basic
and clinical evidence (1,3–7), yet against the prevailing
doctrine. At the present time, chronic neurohormonal acti-
vation is a fundamental concept to understand the mecha-
nisms of disease progression and treatment of HF (8). BB
counterbalance beta-adrenergic activation leading to partial
normalization of increased resting heart rate, filling pressure,
and afterload, collectively blunting the deleterious effect of
persistent hemodynamic stress (9). The beneficial influence
of BB treatment on primary end points such as survival and
HF-related hospitalization has been established by large
randomized controlled trials (RCT) (10–13). Beyond these
unequivocal long-term gains, it seems reasonable to question
about the functional effects of BB treatment, particularly
because the prognosis of HF patients remains poor (14–16).
Peak oxygen consumption (V˙O2peak), as elicited by in-
cremental dynamic exercise (treadmill, bicycle ergometer),
is hallmark of exercise capacity commonly used to deter-
mine eligibility for cardiac transplantation. Irrespective of
the stage of disease, HF patients are characterized by impaired
V˙O2peak (G80% predicted) (17–29). V˙O2peak is a function of
stroke volume (SV), peak heart rate (HRpeak), and oxygen
(O2) extraction, conforming to the Fick principle: V˙O2peak =
SV  HRpeak arteriovenous O2 difference (30). Among the
Fick determinants of V˙O2peak, SV is substantially decreased
in HF patients compared with control individuals (31,32).
Moreover, BB treatment specifically limits HRpeak, reaching
up to 25% decrements (17–20,22–24,26,28,29). Given that
cardiac output (SV  HRpeak), through the regulation of
convective O2 delivery, predominantly determines V˙O2peak,
this could be compromised by BB administration. However,
RCT studies assessing the effect of BB on V˙O2peak or peak
exercise performance as a surrogate have had small sample
sizes and have reported conflicting results (17–29,33–46).
Furthermore, efforts to synthesize a fraction of previous RCT
published until 2005 have delivered varied conclusions (47).
Therefore, the primary purpose of this study was to perform a
systematic review and meta-analysis of RCT assessing the
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effect of prolonged BB treatment on V˙O2peak in HF patients,
as well as to determine the influence of potential clinical and
methodological moderating factors.
METHODS
The review is reported according to the Preferred Reporting
Items for Systematic reviews andMeta-Analyses guidelines (48).
Data sources and searches. The systematic search
included MEDLINE, Scopus, and Web of Science since
their inceptions until March 2017. We used combinations of the
subject headings ‘‘heart failure,’’ ‘‘beta-blocker,’’ ‘‘peak,’’ ‘‘oxygen
consumption,’’ and ‘‘exercise capacity’’; the search strategy for
MEDLINE is shown in Figure, Supplemental Digital Content 1,
MEDLINE search strategy, http://links.lww.com/MSS/B129.
We also performed hand searching in reference citations of
identified reviews, articles included in meta-analysis, and
related citations in MEDLINE and Google Scholar.
Article selection. To be included in the analysis, an
original research article had to meet the following criteria: 1)
RCT involvingHF patients, 2) V˙O2peak reported before and after
BB treatment, and 3) duration of intervention of Q1 month. In
the event of multiple publications pertaining to the same re-
search, the most comprehensive report was included. Inclusion
of articles was not limited by publication status or language.
Data extraction and quality assessment. The fol-
lowing variables were summarized in a preformatted
spreadsheet: authors, year of publication, characteristics of
study participants (n, age, sex, height, weight, New York
Health Association (NYHA) functional class, inclusion/
exclusion criteria, heart rate, left ventricular end-diastolic
volume, left ventricular ejection fraction (LVEF), blood
pressure, smoking status, comorbidities, medication), BB
treatment (agent, type, dose, duration), and exercise capacity
(methodology, V˙O2peak, peak exercise performance). The
methodological quality of each included study was assessed
by the established Jadad scale (49).
Data synthesis and analysis. The meta-analysis was
performed using Review Manager software (RevMan 5.3;
Cochrane Collaboration, Oxford, UK) and Comprehensive
Meta-analysis software (Biostat, Englewood, NJ). The pri-
mary outcome was the standardized mean difference (SMD)
between the effects of BB and placebo treatment on
V˙O2peak. Secondary outcomes included the effects of BB
versus placebo treatment on peak exercise performance (as
determined by peak incremental exercise time or power
output) and NYHA functional class. If the variability of
change (i.e., standard deviation of change (SDc)) for a given
outcome was not reported, the formula
SDc = ¾ [(SDpre)
2 + (SDpost)
2 j (2  corrpre,post  SDpre  SDpost)]
was applied (50). SDpre, SDpost, and corrpre,post represent the
standard deviation of the preintervention value, the standard
deviation of the postintervention value, and the correlation
coefficient between preintervention and postintervention
values, respectively. The corrpre,post was conservatively set at
0.5. Each SMD was weighted by the inverse variance, and it
was pooled with a random-effects model (51). Heterogeneity
among studies was assessed using the chi-squared test for
heterogeneity and I2 statistics.
Potential moderating factors influencing the SMD in
V˙O2peak were evaluated by using subgroup analysis compar-
ing studies grouped by qualitative variables (agent/type of BB
treatment, methodology of exercise testing). In addition,
meta-regression analyses were performed to determine the
association between the SMD in V˙O2peak and potential
moderating quantitative variables (sample size, age, sex, body
mass index, heart rate, left ventricular end-diastolic volume,
LVEF, blood pressure, baseline NYHA functional class,
prevalence of medication, baseline V˙O2peak, year of publica-
tion, methodological quality score). In all meta-regression
models, studies were weighted by the inverse variance of the
dependent variable. Potential moderating factors were entered
as independent variables in regressions models with the SMD
TABLE 1. Main baseline characteristics of studies included in the meta-analysis.
Reference
n Age, yr Female, % LVEF, % MAP, mm Hg NYHA V˙O2peak, mLIkg
j1Iminj1
BB PBO BB PBO BB PBO BB PBO BB PBO BB PBO BB PBO
Conraads et al. (17) 42a 51a 66 T 10b 65 T 11b 65b 64b 945 945 96 95 2.2 T 0.4 2.2 T 0.4 17.0 T 4.8 17.8 T 6.0
Norozi et al. (18) 13 21 29 T 10 32 T 9 15 52 57 T 8 58 T 10 n/a n/a 1.6 T 0.5 1.6 T 0.5 22.0 T 2.0 21.0 T 2.0
Terzi et al. (19) 26a 22a 59 T 10b 60 T 9b 18b 25b 29 T 6b 30 T 7b n/a n/a 2.3 T 0.5 2.3 T 0.5 17.1 T 5.2 14.4 T 4.5
Dubach et al. (20) 13 15 55 T 12 59 T 10 n/a n/a 25 T 7 27 T 13 96 103 2–3 2–3 18.3 T 5.0 18.9 T 3.6
Gullestad et al. (22) 43 40 64 T 11 63 T 9 26 28 26 T 6 27 T 6 n/a n/a 2.6 T 0.5 2.6 T 0.6 15.3 T 3.0 16.0 T 5.7
Hulsmann et al. (21) 23 20 n/a n/a n/a n/a 19 T 5 19 T 5 n/a n/a 2.2 T 0.4 2.3 T 0.4 18.0 T 5.0 17.0 T 4.0
Genth-Zotz et al. (23) 26 26 53 55 31 27 27 T 6 29 T 10 89 96 2.4 T 0.5 2.5 T 0.5 13.5 T 2.8 13.6 T 4.8
Guazzi et al. (24) 14 7 n/a n/a n/a n/a 34 T 6 35 T 6 n/a n/a 2–3 2–3 16.6 T 0.3 17.0 T 0.5
Gilbert et al. (25) 12a 12a 53 T 11b 48 T 12b n/a n/a 23 T 9 21 T 8 88 T 13 85 T 8 2.5 T 0.7b 2.6 T 0.8b 18.7 T 5.1 18.5 T 5.1
Krum et al. (27) 33 16 56 T 13 53 T 14 21 25 17 T 7 16 T 7 88 T 16 78 T 10 2.8 T 0.6 2.8 T 0.8 14.2 T 5.2 13.9 T 5.2
Olsen et al. (26) 32a 23a 54 T 12b 50 T 15b 6b 8b 20 T 6b 19 T 5b 84 T 12b 85 T 5b 2.5 T 0.5b 2.4 T 0.5b 17.5 T 4.5 17.3 T 3.8
Metra et al. (28) 20 20 50 T 10 52 T 10 10 10 20 T 7 20 T 6 90 T 11 91 T 9 2.7 T 0.5 2.8 T 0.4 16.0 T 4.0 15.0 T 3.0
Woodley et al. A (29) 13 9 46 T 11 56 T 24* 31 33 26 T 6 21 T 8 89 T 10 82 T 20 2.4 T 0.4 2.7 T 0.6 20.1 T 4.7 16.4 T 4.2
Woodley et al. B (29) 14a 10a 54 T 12b 53 T 10b 25b 18b 21 T 7b 18 T 8b 84 T 14b 84 T 14b 2.7 T 0.4b 2.7 T 0.3b 15.7 T 2.3 16.2 T 4.7
Data are n, prevalence, mean T SD, or range. One article presented two independent RCT studies (herein distinguished by A and B) (29).
*Significantly different from BB group at P G 0.05.
aSubsample size presenting with V˙O2peak data.
bData from primary sample size.
MAP, mean arterial pressure; n/a, data not available; PBO, placebo group.
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in V˙O2peak as the dependent variable. Publication and/or other
biases were evaluated by the Begg and Mazumdar rank cor-
relation test and Egger regression test (52). A P value of
G0.05 was considered statistically significant.
RESULTS
Study selection and characteristics. The flow dia-
gram of the process of article selection is illustrated in Fig-
ure, Supplemental Digital Content 2, Flow diagram of the
process of article selection, http://links.lww.com/MSS/B130,
which resulted in the inclusion of 13 articles. One of the ar-
ticles presented two independent RCT studies, each of which
was evaluated as an individual study (29). Table 1 shows the
main baseline characteristics of the resulting 14 studies, com-
prising a total of 616 chronic HF patients allocated to BB (n =
324) or placebo (n = 292) treatment. Mean NYHA functional
class and V˙O2peak ranged from 1.6 to 2.8 and from 13.5 to
22 mLIminj1Ikgj1, respectively. Carvedilol was administered in
4 studies (n = 165), metoprolol in 3 studies (n = 159), bisoprolol
in 3 studies (n = 110), nebivolol in 1 study (n = 93), bucindolol
in 2 studies (n = 46), and atenolol in 1 study (n = 43), with
treatment periods of Q3 months (Table 2). Concomitant
reported medication did not differ between BB and placebo
groups (Table 2). All studies assessed V˙O2peak via established
incremental bicycle/treadmill exercise protocols (Table 3).
Effect of BB versus placebo treatment. BB treatment
had no effect on V˙O2peak compared with placebo (n = 616;
SMD, j0.04; 95% confidence interval (CI), j0.20 to 0.12;
P = 0.61) (Fig. 1). No heterogeneity was detected among
studies (I2 = 0%, P = 0.88). Subgroup analyses showed similar
SMD in V˙O2peak between studies assorted by BB treatment
characteristics (agent (P = 0.47), type (P = 0.88)) and exercise
testing methodology (P = 0.25). Likewise, meta-regression
analyses did not reveal any influence of potential moderating
quantitative variables. The effects of BB versus placebo
treatment on secondary outcomes were reported in 11 studies
for peak exercise performance (n = 493) and 7 studies for
NYHA functional class (n = 347). In line with V˙O2peak results,
peak exercise performance did not differ with BB compared
with placebo treatment (n = 493; SMD, 0.02; 95% CI, j0.16
to 0.20; P = 0.85) (Fig. 2). In contrast, NYHA functional class
was improved with BB versus placebo (n = 347; SMD,
j0.54; 95% CI, j0.90 to j0.18; P = 0.003) (Fig. 3).
TABLE 2. BB treatment and prevailing concomitant medication in studies included in the meta-analysis.
Reference
BB Treatment Concomitant Medication, %
Agent Type
Target
Dose, mgIdj1
Duration,
months
ACEi Diuretics Digitalis
BB PBO BB PBO BB PBO
Conraads et al. (17) Nebivolol A1-Selective 10 6 75
a 80a 49a 54a n/a n/a
Norozi et al. (18) Bisoprolol A1-Selective 10 6 n/a n/a 8 5 8 14
Terzi et al. (19) Bisoprolol A1-Selective 5 3 100 100 82
a 83a 63a 68a
Dubach et al. (20) Bisoprolol A1-Selective 10 12 100 100 77 93 38 60
Gullestad et al. (22) Metoprolol A1-Selective 200 11 95 90 86 85 47 45
Hulsmann et al. (21) Atenolol A1-Selective 100 24 100 100 n/a n/a n/a n/a
Genth-Zotz et al. (23) Metoprolol A1-Selective 150 6 92 91 71 71 51 52
Guazzi et al. (24) Carvedilol Nonselective 50 6 n/a n/a 100 100 100 100
Gilbert et al. (25) Metoprolol A1-Selective 150 6 n/a n/a n/a n/a n/a n/a
Krum et al. (27) Carvedilol Nonselective 50 3 94 88 n/a n/a n/a n/a
Olsen et al. (26) Carvedilol Nonselective 50–100 4 100 89a 83a 79a 92a 71a
Metra et al. (28) Carvedilol Nonselective 50 4 95 100 100 100 100 100
Woodley et al. A (29) Bucindolol Nonselective 200 3 71 67a 93 89a 86 89a
Woodley et al. B (29) Bucindolol Nonselective 200 3 n/a n/a n/a n/a n/a n/a
aData from primary sample size.
ACEi, angiotensin-converting enzyme inhibitors; n/a, data not available; PBO, placebo group.
TABLE 3. Exercise testing methodology and peak cardiorespiratory variables in studies included in the meta-analysis.
Reference Ergometer Position Increment Rate
HRpeak, bpm
a V˙ Epeak (LImin
j1)a
BB PBO BB PBO
Conraads et al. (17) Bicycle Upright 20 W every 2 min 127 T 24 132 T 21 n/a n/a
Norozi et al. (18) Bicycle Upright 0.5 WIkgj1 every 2 min 161 T 21 159 T 23 n/a n/a
Terzi et al. (19) Treadmill Upright 2 kmIhj1 every 1 min 143 T 21 149 T 26 40 T 13 37 T 11
Dubach et al. (20) Bicycle Upright Individualized to elicit V˙O2peak in ~10 min 144 T 20 146 T 17 55 T 13 53 T 14
Gullestad et al. (22) Bicycle Upright 20 W every 2 min 141 T 26 133 T 30 49 T 16 45 T 11
Hulsmann et al. (21) Bicycle Upright Individualized n/a n/a n/a n/a
Genth-Zotz et al. (23) Bicycle Semi-supine 10 W every 1 min 123 T 18 121 T 24 42 T 12 44 T 12
Guazzi et al. (24) Bicycle Upright Individualized to elicit V˙O2peak in ~10 min n/a n/a 54 T 6 55 T 6
Gilbert et al. (25) Treadmill Upright 3.5% grade every 2 min n/a n/a n/a n/a
Krum et al. (27) Bicycle Upright n/a n/a n/a n/a n/a
Olsen et al. (26) Bicycle Upright 5–10 W every 1 min 152 T 23 158 T 24 n/a n/a
Metra et al. (28) Bicycle Upright 20 W every 2 min 144 T 21 155 T 21 n/a n/a
Woodley et al. A (29) Treadmill Upright 3.5% grade every 2 min 163 T 22 149 T 21 n/a n/a
Woodley et al. B (29) Treadmill Upright 3.5% grade every 2 min 145 T 23b 136 T 28b n/a n/a
Data are mean T SD.
aBaseline data.
bData from primary sample size.
n/a, data not available; PBO, placebo group; V˙Epeak, peak minute ventilation.
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Methodological quality assessment and potential
bias. The methodological quality of the studies was mod-
erate to high (see Table, Supplemental Digital Content 3,
Quality assessment of studies included in the meta-analysis,
http://links.lww.com/MSS/B131). The average Jadad score
(49) was 3.0 T 0.8 out of a possible 5 points, ranging from 2
to 4 points. All studies were RCT, 13 of them reported as
double-blind trials. Nine studies had adequately described
dropouts, whereas the rest did not comment on dropouts. With
respect to the evaluation of potential biases, the Begg and
Mazumdar rank correlation test (P = 0.91), Egger regression
test (P = 0.51), and the funnel plot (see Figure, Supplemental
Digital Content 4, Funnel plot of the SMD in V˙O2peak, http://
links.lww.com/MSS/B132) (52,53) did not suggest the pres-
ence of publication bias and/or other biases regarding the
SMD in V˙O2peak in the studies included in the meta-analysis.
DISCUSSION
In this systematic review and meta-analysis, we pooled
and analyzed data from 14 RCT studies assessing the effect
of BB interventions ranging from 3 to 24 months of dura-
tion on V˙O2peak in a total of 616 HF patients. The main
finding of this meta-analysis is that prolonged BB ad-
ministration does not affect V˙O2peak, an outcome that was
remarkably consistent across varied BB intervention char-
acteristics. Likewise, peak exercise performance remained
unaltered, albeit NYHA functional class was improved with
BB treatment.
A therapy may be judged thoroughly successful if it pro-
longs and ameliorates the quality of life. Functional gains
are particularly relevant in the context of disease such as
HF in which treatment-induced increases in longevity are
exiguous (15,54). That BB administration attenuates he-
modynamic stress and blunts chronotropic responsiveness
suggests a limitation of cardiac pumping capacity and
thereby V˙O2peak. Results from this meta-analysis indicate
that V˙O2peak is preserved with prolonged BB treatment,
although marked decrements in HRpeak were noted in most
of the studies (17–20,22–24,26,28,29). Hence, BB may
induce compensating adaptations in ventricular function
enhancing SV to maintain cardiac output and convective
FIGURE 1—Forest plot of the SMD between the effects of BB and placebo treatment on V˙O2peak in HF patients. Squares represent the SMD for each
study. Diamonds represent the pooled SMD across studies. df, degrees of freedom; IV, inverse variance; SD, standard deviation.
FIGURE 2—Forest plot of the SMD between the effects of BB and placebo treatment on peak exercise performance in HF patients. Squares represent
the SMD for each study. Diamonds represent the pooled SMD across studies. df, degrees of freedom; IV, inverse variance; SD, standard deviation.
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O2 delivery (23,24). Indeed, resting LVEF increased by
6%–18% with BB treatment (20,21,23–25,27–29). Lim-
ited evidence denotes similar BB-related improvements in
LVEF at peak exercise or with atrial pacing (23,55). Un-
derlying mechanisms can include a partial reversal of
ventricular remodeling (24,56) and improved myocardial
metabolism (57,58) leading to reduced filling pressure/SV
ratio implying a shift in the operating point to a steeper
portion of the Frank–Starling curve (57). In addition, the
robust effect of BB on V˙O2peak should be remarked as
demonstrated by the null heterogeneity among studies in-
volving distinct intervention features as regards BB agent,
type, target dose, and duration. This suggests the presence of
a generalized homeostatic regulation of cardiac output in re-
sponse to prolonged BB treatment in HF.
Beta-adrenergic blockade may interfere with skeletal
muscle metabolism during exercise (59). A1-Selective BB
and nonselective BB inhibit lypolysis (60), whereas nonselective
BB specifically decreases energy flux through glycogenolysis,
leading to delayed glycolysis (61,62). This implies a limi-
tation of muscle contraction at high exercise intensities,
known to primarily depend on glycolysis for energy pro-
duction (63). The negative influence of acute BB admin-
istration on peak exercise performance has been previously
described in healthy individuals, being more pronounced
with nonselective than with A1-selective BB (60). In con-
trast, short-term (e1 wk) BB administration does to affect
incremental exercise time in HF patients, irrespective of
type of BB (28,64,65). Similarly, in the present meta-
analysis, peak exercise performance remained consistently
unaltered after prolonged BB treatment. The divergence
between healthy individuals and HF patients could be re-
lated to intrinsic abnormalities in skeletal muscle metabo-
lism. Exercising skeletal muscle in HF patients is characterized
by the overactivation of glycogenolysis associated with an
earlier shift to glycolytic metabolism expediting muscle
dysfunction (66). This might be partially corrected by
nonselective BB, facilitated by the aforementioned retarda-
tion of glucose metabolism (67). Furthermore, nonselective
BB and A1-selective BB prevent muscle atrophy, thus less-
ening the recession of muscle cross-sectional area and
strength in HF patients (68,69).
At variance with measures of exercise capacity, NYHA
functional class was improved by BB treatment. In the NYHA
scheme, patients are classified into four categories ordered
from least to most severe HF according to the extent of
symptoms (shortness of breath, angina) at rest and during
habitual physical activity (70). Notwithstanding the subjective
nature of this assessment, BB-induced reduction of NYHA
functional class could be attributed to changes in ventilation,
which for a given work rate is inappropriately increased in HF
patients because of augmented ergoflex and chemoreflex.
Substantial decreases (up to 20% decrements) in ventilation
during submaximal exercise have been reported in HF pa-
tients after nonselective and A1-selective BB treatment
(71,72). BB may enhance ventilatory efficiency by decreas-
ing the ventilation/carbon dioxide output slope (71), although
this is not a universal finding (24,73). Alternatively, stimuli
that activate ventilation such as carbon dioxide output and
muscle acidosis could be reduced by nonselective BB through
the aforementioned limitation of skeletal muscle glycolytic
metabolism and lactate production (73,74). Ultimately, the
effects of BB on ventilation may translate into improved
symptoms derived from the attenuation of breathing dis-
comfort and the early feeling of fatigue, which are partly
dissociated from V˙O2peak (75,76).
LIMITATIONS
First, most of the studies included patients with HF and
reduced LVEF (G40%), which approximately comprise half
of the HF population; thus, our conclusions should be con-
fined accordingly. The exclusion of the two studies includ-
ing patients with HF and preserved LVEF did not alter the
SMD in V˙O2peak (SMD, 0.00; P = 0.99), peak exercise
performance (SMD, 0.03; P = 0.79), and NYHA functional
class (SMD, j0.65; P G 0.001) (17,18). Second, BB effects
could be influenced by concomitant standard HF pharma-
cotherapy. Nonetheless, heterogeneity statistics did not
reveal any moderating effect of reported medications, and
the SMD in V˙O2peak was rather uniform among studies.
Third, one study did not explicitly report the use of pla-
cebo in the control group (19). The exclusion of this study
did not alter the results of this meta-analysis. Finally, the mean
FIGURE 3—Forest plot of the SMD between the effects of BB and placebo treatment on NYHA functional class in HF patients. Squares represent the
SMD for each study. Diamonds represent the pooled SMD across studies. df, degrees of freedom; IV, inverse variance; SD, standard deviation.
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methodological quality of the included studies was determined
as moderate to high, and no publication bias and/or other biases
were detected.
CONCLUSIONS
The current meta-analysis demonstrates that V˙O2peak is
preserved with BB treatment in HF patients. Moreover, al-
though V˙O2peak and peak exercise performance remained
unaltered, BB treatment elicited positive effects in the
functional status determined by the NYHA functional class,
possibly attributed to reduced ventilatory overactivation.
These findings contribute to clarify the effect of BB ad-
ministration on exercise capacity and symptom relief in pa-
tients with HF.
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